Amisulpride is an antagonist of 5-HT7 receptor and dopamine D2 and D3 receptors. It modulates beta 2- arresting signaling and increases neurite outgrowth.

Sultopride is a compound that an amino on the sulfamide group of sulpiride is replaced by an ethyl group.

(S)-Amisulpride ((S) Amisulpride) (Esamisulpride) is a potent dopamine D2/D3 receptor antagonist. (S)-Amisulpride is an antagonist at the 5-HT7 receptor with a Ki of 900 nM. (S)-Amisulpride has antipsychotic and antidepressant effects.

Amisulpride (DAN 2163) (trade name Solian) is an antipsychotic drug sold by Sanofi-Aventis. It is not approved for use in the United States, but is approved for use in Europe and Australia for the treatment of psychoses and schizophrenia. Additionally, it is approved in Italy for the treatment of dysthymia (under the brand name Deniban). Amisulpride is a selective dopamine antagonist.

Sultopride hydrochloride (LIN-1418 hydrochloride) is a selective dopamine D2 and D3 receptor antagonist.